Pyrimidine compounds
    9.
    发明授权
    Pyrimidine compounds 有权
    嘧啶化合物

    公开(公告)号:US06693097B2

    公开(公告)日:2004-02-17

    申请号:US10000742

    申请日:2001-11-30

    IPC分类号: C07D41704

    摘要: This invention features pyrimidine compounds of formula (I): aryl, or heteroaryl; each of R2 and R4, independently, is Rc, halogen, nitro, cyano, isothionitro, SRc, or ORc; or R2 and R4, taken together, is carbonyl; R3 is Rc, alkenyl, alkynyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(O2), or NRc; Y is a covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc; Z is N or CH; one of U and V is N, and the other is CRc; and W is O, S, S(O), S(O2), NRc, or NC(O)Rc; in which each of Ra and Rb, independently, is H, alkyl, aryl, heteroaryl; and each of Rc and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl.

    摘要翻译: 本发明的特征在于式(I)的嘧啶化合物:芳基或杂芳基; R 2和R 4各自独立地是R c,卤素,硝基,氰基,异硫代,SR c或OR c; 或R 2和R 4一起是羰基; R 3是R c,链烯基,炔基,OR c,OC(O)R c,SO 2 R c,S(O)R c,S(O 2)NR c NR c C(O)OR d,NR c C(O)NR c, R d,NR c,SO 2 R d,COR c,C(O)OR c或C(O)NR c R d; R5是H或烷基; n是0,1,2,3,4,5或6; X是O,S,S(O),S(O 2)或NR c; Y是共价键,CH 2,C(O),C = NR c,C = N-OR c,C = N-SR c,O,S,S(O) )或NR ; Z是N或CH; U和V之一是N,另一个是CR ; 并且W是O,S,S(O),S(O 2),NR c或NC(O)R c; 其中R 1和R 2各自独立地是H,烷基,芳基,杂芳基; R c和R d各自独立地是H,烷基,芳基,杂芳基,环基,杂环基或烷基羰基。

    Heterocyclic compounds
    10.
    发明授权

    公开(公告)号:US07410990B2

    公开(公告)日:2008-08-12

    申请号:US11542963

    申请日:2006-10-03

    摘要: This invention features a compound of formula (I): R1 is aryl or heteroaryl; each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb; R3 is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORa, OC(O)Ra, OC(O)NRaRb, NRaRb, NRaC(O)Rb, NRaS(O)RbNRaS(O)2Rb, NRaC(O)NRbRc, NRaC(S)NRbRc, NRaC(NRb)NRcRd, NRaC(O)ORb, S(O)NRaRb, S(O)2NRaRb, S(O)Ra, S(O)2Ra, C(O)Ra, C(O)ORa, or C(O)NRaRb; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; A is O, S, S(O), S(O)2, or NRe; B is N or CRf; X is O, S, S(O), S(O)2, NRe, or C(O); Y is a covalent bond, C(O), C═NRa, O, S, S(O), S(O)2, or NRe; Z is N or CH; each of U and V, independently, is N or CR; and W is O, S, or NRe; in which each of Ra, Rb, Rc, and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; Re is H, alkyl, aryl, acyl, or sufonyl; and Rf is H, alkyl, aryl, acyl, sulfonyl, alkoxyl, amino, ester, amide, CN, or halogen. The compound is useful for treating an interleukin-12 overproduction-related disorder.